

CURE

Beyond
CIRM 2.0
CALIFORNIA'S STEM CELL AGENCY

now it's personal



Gil Sambrano, Ph.D.

Director of Portfolio Development and Review

HOPE

Funding Opportunities



DISCOVERY



TRANSLATION



CLINICAL

New Idea



Single Product Candidate



Pre-IND Meeting or Equivalent



Approved Therapy



1-2/Year



3/Year



12/Year

Program Offerings Per Year

CIRM Translation Research Program (TRAN)



Objective


To support promising stem cell-based projects that accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use.

What qualifies for TRAN?

Projects that propose a candidate:

- Therapeutic (TRAN 1)
- Diagnostic (TRAN 2)
- Medical device (TRAN 3)
- Tool (TRAN4)

CIRM 2.0: Translation Program



Review Criteria

- ✓ Does the project hold the necessary significance and potential for impact?
- ✓ Is the rationale sound?
- ✓ Is the project well planned and designed?
- ✓ Is the project feasible?

Scoring System

- **Score of “85-100”**

Recommended for funding, if funds are available

- **Score of “1-84”**

Not recommended for funding

Applications are scored by all scientific members of the GWG with no conflict.

The **median** of all individual GWG scores determines final score.

GWG Recommendations



	Number of Apps	Total Applicant Request	Funds Available
Recommended for funding Score 85-100	1	\$5,795,584	~\$40,900,000
Not recommended for funding Score 1-84	8		

For each award, the final award amount shall not exceed the amount approved by the ICOC Application Review Subcommittee and may be reduced contingent on CIRM's assessment of allowable costs and activities.

Overview of Recommended Applications

TRAN1-10258

TITLE: Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies

APPLICATION: Treatment for multiple CSC-based malignancies

PRODUCT TYPE: Cell therapy targeting CSC